The current shortage of Acyclovir, CAS number 59277-98-3, is of great concern to the medical community. As a valued and integral treatment for encephalitis, the shortage of Acyclovir for compounding pharmacies has created an urgent need for both patients and practitioners. The August 27, 2013 issue of the Neurology journal cautioned healthcare professionals to be[…]
Shortage of Acyclovir Leads to Dire Situation for Patients with Encephalitis
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, FDA Drug Shortage, OTC and Compounding Product, Patent Expiration 2017 Sep 18, 2013
Profitable Sitagliptin is a Best Selling Pharmaceutical Product
Anti-Diabetic, Patent Expiration 2017 Tags: Januviasitagliptintype 2 Diabetes May 13, 2013
The patent for the phenomenal Sitagliptin, known as the brand name Januvia, is set to expire on April 24, 2017. As a blockbuster drug sitagliptin, CAS number 486460-32-6, is set up for undoubted success as a generic drug. Sales of Januvia in both the United States and Japan are extremely strong, so much so that[…]
New Trial for Linagliptin and Patients with Type 2 Diabetes
Anti-Diabetic, Patent Expiration 2017 Tags: HbA1cLinagliptintype 2 Diabetes May 08, 2013
Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on March 19, 2013 the initiation of a novel clinical trial for linagliptin. Coined MARLINA, this Phase IIIb trial will evaluate the glycemic efficacy and safety of linagliptin in patients with type 2 diabetes who have prevalent albuminuria. This patient population, suffering from albuminuria, will[…]
Tadalafil Alongside Finasteride Once Daily Improved IPSS For Men
Blood Product, Cardiovascular Agent, OTC and Compounding Product, Patent Expiration 2017, TEVA API Tags: erectile dysfunction May 06, 2013
Tadalafil, also known as Cialis, is making headlines in pharmaceutical news. A study released on March 18, 2013 touted the use of tadalafil alongside finasteride for sizably improving scores for men on the International Prostate Symptom Score. Marketed by Eli Lilly, the patent for Cialis expires on November 21, 2017. The study, which was revealed[…]
Can Testosterone Be Used As a Preventative Treatment For Type 2 Diabetes In Men?
Anti-Diabetic, Drug Research & Development API, Hormonal Agent, OTC and Compounding Product, Patent Expiration 2017 Tags: AustraliaCDCtype 2 Diabetes Apr 22, 2013
Is Testosterone a potential preventative treatment for type 2 diabetes? Researchers at the University of Adelaide in Australia are hopeful that their latest research will be the kick-start for trials of testosterone as a preventative for this encompassing from of diabetes. Results from early stages of this current study, which were discussed at the 10th[…]
New Tenofovir Pro-Drug Offers Less Toxicity
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2017 Tags: HIVHIV infectionHIV virus Mar 25, 2013
On March 6, 2013 The Physician’s Weekly reported that a new Tenofovir Pro-Drug had less potential for bone and kidney toxicity, but still remained efficacious as a treatment for both Hepatitis and HIV infection. The findings were revealed at the 20th Conference on Retroviruses and Opportunistic Infections 2013 in Atlanta, Georgia. Tenofovir is a vastly[…]
Can Ritonavir Boosted Fosamprenavir Lead to a Cure for AIDS?
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2017 Tags: AIDSHIV virusNorvirRitonavir Mar 07, 2013
The recent headlines proclaiming a cure for a Mississippi baby who had been exposed to the HIV virus which causes AIDS have captivated the world. This child was born to an HIV positive mother who had not received any prenatal care to reduce the transmission of the virus. Dr. Hannah Gay, who treated the baby,[…]
Could Gabapentin Have Helped Kate Middleton- and Can it Help All Women with Hyperemesis Gravidarum?
Analgesic, Anti-Parkinsons, Bulk Active Ingredient, Drug Research & Development API, OTC and Compounding Product, Patent Expiration 2017 Tags: epilepsy Mar 05, 2013
Gabapentin, also known as Neurontin, has long been a stable and effective treatment for patients who experience seizures, certain forms of epilepsy and pain from shingles. New research has indicated another effectual use for Gabapentin, CAS 60142-96-3, as a treatment to help combat symptoms of severe morning sickness. Known as hyperemesis gravidarum, this extreme form[…]
Zmax is Azithromycin to the Max
Antibiotic, Bulk Active Ingredient, Patent Expiration 2017, TEVA API Tags: Pfizer Mar 04, 2013
The patent for the omnipotent Zmax is set to expire for Pfizer on May 30, 2017. This is extremely relevant for research and development as a generic formulation of this cogent drug, specifically azithromycin, can now be produced. Azithromycin is indicated for mild to moderate infections including acute bacterial sinusitis in adults due to haemophilus[…]
FDA Approves New Indication for Budesonide
Anti-Asthma / COPD, Anti-Inflammatory, Bulk Active Ingredient, Drug Research & Development API, OTC and Compounding Product, Patent Expiration 2017 Tags: asthma Feb 18, 2013
On January 15, 2013 Santarus, Inc. announced that the FDA had approved Budesonide, as the brand name Ulceris, for the induction of remission in patients with mild, moderate and active forms of ulcerative colitis. As an extended release tablet, this new indication approval of budesonide is a vital and novel therapeutic option for patients. Adult[…]
